Skip NavigationSkip to Content
Return Return to Search Results

Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity

  1. Author:
    Scott, Jack D.
    DeMong, Duane E.
    Greshock, Thomas J.
    Basu, Kallol
    Dai, Xing
    Harris, Joel
    Hruza, Alan
    Li, Sarah W.
    Lin, Sue-Ing
    Liu, Hong
    Macala, Megan K.
    Hu, Zhiyong
    Mei, Hong
    Zhang, Honglu
    Walsh, Paul
    Poirier, Marc
    Shi, Zhi-Cai
    Xiao, Li
    Agnihotri, Gautam
    Baptista, Marco A. S.
    Columbus, John
    Fell, Matthew J.
    Hyde, Lynn A.
    Kuvelkar, Reshma
    Lin, Yinghui
    Mirescu, Christian
    Morrow, John A.
    Yin, Zhizhang
    Zhang, Xiaoping
    Zhou, Xiaoping
    Chang, Ronald K.
    Embrey, Mark W.
    Sanders, John M.
    Tiscia, Heather E.
    Drolet, Robert E.
    Kern, Jonathan T.
    Sur, Sylvie M.
    Renger, John J.
    Bilodeau, Mark T.
    Kennedy, Matthew E.
    Parker, Eric M.
    Stamford, Andrew W.
    Nargund, Ravi
    McCauley, John A.
    Miller, Michael W.

  2. Author Address

    Merck & Co Inc, 2015 Galloping Hill Rd, Kenilworth, NJ 07033 USA.Merck & Co Inc, 33 Ave Louis Pasteur, Boston, MA 02115 USA.Merck & Co Inc, 770 Sumneytown Pike, West Point, PA 19486 USA.Merck & Co Inc, 126 East Lincoln Ave, Rahway, NJ 07065 USA.HB Fuller, Vadnais Hts, MN 55110 USA.AECOM, Pittsburgh, PA 15219 USA.WuXi AppTec, Plainsboro, NJ 08536 USA.Michael J Fox Fdn, New York, NY 10018 USA.Leidos Biomed Res Inc, Frederick, MD 21701 USA.IOmet Pharm, Edinburgh EH16 4UX, Midlothian, Scotland.AbbVie, N Chicago, IL 60064 USA.Purdue Pharma, Stamford, CT 06901 USA.Tarveda Therapeut Watertown, Watertown, MA 02472 USA.
    1. Year: 2017
    2. Date: 2017-04-13
  2. Journal: JOURNAL OF MEDICINAL CHEMISTRY
  3. AMER CHEMICAL SOC,
    1. 60
    2. 7
    3. Pages: 2983-2992
  5. Type of Article: Article
  6. ISSN: 0022-2623
  1. Abstract:

    Leucine-rich repeat kinase 2 (LRRK2) is a large, multidomain protein which contains a kinase domain and GTPase domain among other regions. Individuals possessing gain of function mutations in the kinase domain such as the most prevalent G2019S mutation have been associated with an increased risk for the development of Parkinson's disease (PD). Given this genetic validation for inhibition of LRRK2 kinase activity as a potential means of affecting disease progression, our team set out to develop LRRK2 inhibitors to test this hypothesis. A high throughput screen of our compound collection afforded a number of promising indazole leads which were truncated in order to identify a minimum pharmacophore. Further optimization of these indazoles led to the development of MLi-2 (1): a potent, highly selective, orally available, brain-penetrant inhibitor of LRRK2.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1021/acs.jmedchem.7b00045
  3. View record in Web of Science®
  4. WOS: 000399436100025

Library Notes

  1. Fiscal Year: FY2016-2017
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel